<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Paraskevis, D</style></author><author><style face="normal" font="default" size="100%">Magiorkinis, E</style></author><author><style face="normal" font="default" size="100%">Katsoulidou, A</style></author><author><style face="normal" font="default" size="100%">Hatzitheodorou, E.</style></author><author><style face="normal" font="default" size="100%">Antoniadou, A</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, A.</style></author><author><style face="normal" font="default" size="100%">Poulakou, G</style></author><author><style face="normal" font="default" size="100%">Paparizos, V</style></author><author><style face="normal" font="default" size="100%">Botsi, C.</style></author><author><style face="normal" font="default" size="100%">Stavrianeas, N</style></author><author><style face="normal" font="default" size="100%">Lelekis,M.</style></author><author><style face="normal" font="default" size="100%">Chini, M</style></author><author><style face="normal" font="default" size="100%">Gargalianos, P</style></author><author><style face="normal" font="default" size="100%">Magafas, N.</style></author><author><style face="normal" font="default" size="100%">Lazanas, M</style></author><author><style face="normal" font="default" size="100%">Chryssos, G</style></author><author><style face="normal" font="default" size="100%">Petrikkos, G</style></author><author><style face="normal" font="default" size="100%">Panos, G.</style></author><author><style face="normal" font="default" size="100%">Kordossis, T.</style></author><author><style face="normal" font="default" size="100%">Theodoridou, M.</style></author><author><style face="normal" font="default" size="100%">Sypsa, V</style></author><author><style face="normal" font="default" size="100%">Hatzakis, A</style></author><author><style face="normal" font="default" size="100%">Hellenic Multi-centre study on, H. I. V. resistance</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Prevalence of resistance-associated mutations in newly diagnosed HIV-1 patients in Greece</style></title><secondary-title><style face="normal" font="default" size="100%">Virus ResVirus ResVirus Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Virus research</style></alt-title><short-title><style face="normal" font="default" size="100%">Virus researchVirus research</style></short-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">*Mutation</style></keyword><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Anti-HIV Agents/pharmacology</style></keyword><keyword><style  face="normal" font="default" size="100%">Drug Resistance, Viral/*genetics</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Greece/epidemiology</style></keyword><keyword><style  face="normal" font="default" size="100%">HIV Infections/diagnosis/*epidemiology/*virology</style></keyword><keyword><style  face="normal" font="default" size="100%">HIV Protease Inhibitors/pharmacology</style></keyword><keyword><style  face="normal" font="default" size="100%">HIV Protease/genetics</style></keyword><keyword><style  face="normal" font="default" size="100%">HIV Reverse Transcriptase/genetics</style></keyword><keyword><style  face="normal" font="default" size="100%">HIV-1/classification/*drug effects/genetics</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Microbial Sensitivity Tests/methods</style></keyword><keyword><style  face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style  face="normal" font="default" size="100%">Reverse Transcriptase Inhibitors/pharmacology</style></keyword><keyword><style  face="normal" font="default" size="100%">Sequence Analysis, DNA</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2005</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">1-2</style></number><volume><style face="normal" font="default" size="100%">112</style></volume><pages><style face="normal" font="default" size="100%">115-22</style></pages><isbn><style face="normal" font="default" size="100%">0168-1702 (Print)0168-1702 (Linking)</style></isbn><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">The prevalence of HIV-1 drug resistance mutations in naive patients has been previously shown to differ greatly with the geographic origin. The purpose of this study was to prospectively estimate the prevalence of HIV-1 drug resistance in Greece by analyzing a representative sample of newly HIV-1 diagnosed patients, as part of the SPREAD collaborative study. Protease (PR) and partial reverse transcriptase (RT) sequences were determined from 101 newly diagnosed HIV-1 patients, in Greece, during the period September 2002--August 2003, representing one-third of the total newly diagnosed HIV-1 patients in the same time period. The prevalence of HIV-1 drug resistance was estimated according to the IAS-USA mutation table taking into account all mutations in RT and only major mutations in PR region. The overall prevalence of resistance was 9% [95% confidence interval (CI): 4.2--16.2%]. The prevalence of mutations associated with resistance to NRTIs was 5% (95% CI: 1.6--11.2%), for NNRTIs was 4% (95% CI: 1.1--9.8%), while no major resistance mutations were found in PR. No multi-class resistance was detected in the study population. The prevalence of resistant mutations in the recent seroconverters was 22%. For two individuals, there was clear evidence for transmitted resistance based on epidemiological information for a known source of HIV-1 transmission. The prevalence of the HIV-1 non-B subtypes and recombinants was 52%.</style></abstract><accession-num><style face="normal" font="default" size="100%">16022906</style></accession-num><notes><style face="normal" font="default" size="100%">Paraskevis, DMagiorkinis, EKatsoulidou, AHatzitheodorou, EAntoniadou, APapadopoulos, APoulakou, GPaparizos, VBotsi, CStavrianeas, NLelekis, MChini, MGargalianos, PMagafas, NLazanas, MChryssos, GPetrikkos, GPanos, GKordossis, TTheodoridou, MSypsa, VHatzakis, AengResearch Support, Non-U.S. Gov'tNetherlands2005/07/19 09:00Virus Res. 2005 Sep;112(1-2):115-22. doi: 10.1016/j.virusres.2005.03.004. Epub 2005 Apr 8.</style></notes><auth-address><style face="normal" font="default" size="100%">Department of Hygiene and Epidemiology, Athens University Medical School, Mikras Asias 75, GR-11527 Athens, Greece. dparask@cc.uoa.gr</style></auth-address></record></records></xml>